Mallinckrodt (NYSE: MNK) will present new data for two of its recently approved pain medications – XARTEMIS™ XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII) and PENNSAID® 2% (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%) – during the 33rd Annual Scientific Meeting of the American Pain Society (APS) to be held April 30 - May 3, 2014 in Tampa, Florida.
Help employers find you! Check out all the jobs and post your resume.
